These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38465427)

  • 1. Associations of Patients with Pericardial Effusion Secondary to Light-Chain or Transthyretin Amyloidosis- A Systematic Review.
    Javed N; Singh K; Shirah J; Vittorio TJ
    Curr Cardiol Rev; 2024; 20(4):e080324227805. PubMed ID: 38465427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac amyloidosis is not a single disease: a multiparametric comparison between the light chain and transthyretin forms.
    Neculae G; Adam R; Jercan A; Bădeliță S; Tjahjadi C; Draghici M; Stan C; Bax JJ; Popescu BA; Marsan NA; Coriu D; Jurcuț R
    ESC Heart Fail; 2024 Oct; 11(5):2825-2834. PubMed ID: 38757395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and imaging characteristics of patients with cardiac amyloidosis- a single center observational study.
    Ingebrigtsen A; Saeed S; Larsen TH; Reikvam H
    Scand J Clin Lab Invest; 2024 May; 84(3):193-201. PubMed ID: 38709651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atrial function and geometry differences in transthyretin versus immunoglobulin light chain amyloidosis: a cardiac magnetic resonance study.
    Palmer C; Truong VT; Slivnick JA; Wolking S; Coleman P; Mazur W; Zareba KM
    Sci Rep; 2022 Jan; 12(1):140. PubMed ID: 34996915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis.
    Papathanasiou M; Jakstaite AM; Oubari S; Siebermair J; Wakili R; Hoffmann J; Carpinteiro A; Hagenacker T; Thimm A; Rischpler C; Kessler L; Rassaf T; Luedike P
    ESC Heart Fail; 2022 Jun; 9(3):1740-1748. PubMed ID: 35178887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implications of pericardial and pleural effusion in patients with cardiac amyloidosis.
    Binder C; Duca F; Binder T; Rettl R; Dachs TM; Seirer B; Camuz Ligios L; Dusik F; Capelle C; Qin H; Agis H; Kain R; Hengstenberg C; Badr Eslam R; Bonderman D
    Clin Res Cardiol; 2021 Apr; 110(4):532-543. PubMed ID: 32914241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality.
    Sanchis K; Cariou E; Colombat M; Ribes D; Huart A; Cintas P; Fournier P; Rollin A; Carrié D; Galinier M; Maury P; Duparc A; Lairez O;
    Amyloid; 2019 Sep; 26(3):128-138. PubMed ID: 31172799
    [No Abstract]   [Full Text] [Related]  

  • 8. Differences in the characteristics and contemporary cardiac outcomes of patients with light-chain versus transthyretin cardiac amyloidosis.
    Itzhaki Ben Zadok O; Vaturi M; Vaxman I; Iakobishvili Z; Rhurman-Shahar N; Kornowski R; Hamdan A
    PLoS One; 2021; 16(8):e0255487. PubMed ID: 34370783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parametric mapping using cardiovascular magnetic resonance for the differentiation of light chain amyloidosis and transthyretin-related amyloidosis.
    Kravchenko D; Isaak A; Zimmer S; Öztürk C; Mesropyan N; Bischoff LM; Voigt M; Ginzburg D; Attenberger U; Pieper CC; Kuetting D; Luetkens JA
    Eur Heart J Cardiovasc Imaging; 2024 Sep; 25(10):1451-1461. PubMed ID: 38912832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Data on ATTR-Amyloidosis Prevalence Among Elderly Patients With Left Ventricular Hypertrophy in Russia.
    Nikiforova TV; Charaya KV; Shchekochikhin DY; Magomedova ZM; Enokyan MS; Volovchenko AN; Khamzatkhanova AH; Starovoytova TA; Bogdanova AA; Karalkin AV; Pasha SP; Pershina ES; Grachev AE; Zhirov IV; Andreev DA
    Kardiologiia; 2024 Apr; 64(4):54-60. PubMed ID: 38742516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
    Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
    JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal Echocardiographic Parameters to Improve the Diagnostic Yield of Tc-99m-Bone Avid Tracer Cardiac Scintigraphy for Transthyretin Cardiac Amyloidosis.
    Cuddy SA; Datar Y; Ovsak G; Saith S; Murphy SP; Bay CP; Haddad M; Lilleness B; Muralidhar V; Pipilas A; Vuong J; Guardino E; Maurer MS; Ruberg FL; Falk RH; Dorbala S
    Circ Cardiovasc Imaging; 2022 Nov; 15(11):e014645. PubMed ID: 36378779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of screening biopsies in light-chain (AL) and transthyretin (ATTR) amyloidosis.
    Cohen OC; Sharpley F; Gilbertson JA; Wechalekar AD; Sachchithanantham S; Mahmood S; Whelan CJ; Martinez-Naharro A; Fontana M; Lachmann HJ; Hawkins PN; Gillmore JD
    Eur J Haematol; 2020 Sep; 105(3):352-356. PubMed ID: 32495369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study.
    Fontana M; Banypersad SM; Treibel TA; Abdel-Gadir A; Maestrini V; Lane T; Gilbertson JA; Hutt DF; Lachmann HJ; Whelan CJ; Wechalekar AD; Herrey AS; Gillmore JD; Hawkins PN; Moon JC
    Radiology; 2015 Nov; 277(2):388-97. PubMed ID: 25997029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value.
    Cipriani A; De Michieli L; Porcari A; Licchelli L; Sinigiani G; Tini G; Zampieri M; Sessarego E; Argirò A; Fumagalli C; De Gaspari M; Licordari R; Russo D; Di Bella G; Perfetto F; Autore C; Musumeci B; Canepa M; Merlo M; Sinagra G; Gregori D; Iliceto S; Perazzolo Marra M; Cappelli F; Rapezzi C
    JACC CardioOncol; 2022 Nov; 4(4):458-470. PubMed ID: 36444225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities.
    Orini M; Graham AJ; Martinez-Naharro A; Andrews CM; de Marvao A; Statton B; Cook SA; O'Regan DP; Hawkins PN; Rudy Y; Fontana M; Lambiase PD
    J Am Heart Assoc; 2019 Sep; 8(18):e012097. PubMed ID: 31496332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis.
    Brownrigg J; Lorenzini M; Lumley M; Elliott P
    ESC Heart Fail; 2019 Oct; 6(5):1041-1051. PubMed ID: 31487121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence, Incidence, and Impact on Mortality of Conduction System Disease in Transthyretin Cardiac Amyloidosis.
    Donnellan E; Wazni OM; Saliba WI; Hanna M; Kanj M; Patel DR; Wilner B; Kochar A; Jaber WA
    Am J Cardiol; 2020 Aug; 128():140-146. PubMed ID: 32650908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transthyretin amyloid cardiomyopathy in patients with unexplained increased left ventricular wall thickness.
    Holcman K; Kostkiewicz M; Szot W; Ćmiel B; Mróz K; Stępień A; Graczyk K; Dziewięcka E; Karabinowska-Małocha A; Sachajko Z; Podolec P; Rubiś P
    Int J Cardiovasc Imaging; 2024 Aug; 40(8):1693-1703. PubMed ID: 38856962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards a Diagnosis of Cardiac Amyloidosis: Single Center Experience with
    Saleem M; Sadat B; Van Harn M; Ananthasubramaniam K
    Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837580
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.